Knoll Pharma open offer: Pros and cons - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Knoll Pharma open offer: Pros and cons

May 7, 2001

Abbott Laboratories Inc has made an open offer to the shareholders of Knoll Pharma to acquire 20% of the company’s equity at Rs 328 per share. This follows Knoll Pharma’s parent company’s sell-out to Abbott Inc. Is it worth for Knoll Pharma shareholders to consider this option? Let’s take a look at a few things to evaluate this offer.

  • Knoll Pharma is a leading player in the domestic insulin, anti-diabetic, (with a market leadership in insulin therapy) pain control, and antacid market. Leading brands from the company’s stable include Brufen (anti- rheumatic), Diegen (anti-acid), Epilex (anti–epilepsy) and Cremmafin (laxative).

  • It has a high DPCO exposure of more than 62%. Imminent changes in industry led by dilution in DPCO would be a big upside for Knoll considering that 62 per cent of its turnover comes from price-controlled products. Moreover, company has received 22 per cent hike in insulin formulation which accounts for 41 per cent of turnover in 2000 – Rs 1.4 bn) in April 2001. This is expected to improve performance in FY 2001. Knoll Pharma : Better days ahead

  • Abbott Inc also has a 51% subsidiary viz, Abbott Laboratories India, which has major presence in vitamins, anti-infective, hospital and diagnostic products. Of the multinational pharma companies operating in India, Abbott is one of the few companies with a portfolio extending to hospital products and pediatric nutrition. The product portfolio of the company seems to be complimentary with Knoll Pharma.

  • At the current market price Knoll Pharma is trading at just 10 times its expected earnings for FY02.

Shareholding Pattern of Knoll Pharma % of Holding
Indian Promoters and Foreign Collaborators 56.7
Institutions and Mutual Funds 14.3
FII’s/GDR 3.3
Free Float 25.7

At the current market price of Rs 304, the open offer price (Rs 328) is at a 8% premium. Abbott will find it difficult to entice a 20% shareholding from the offer considering there is only 26% equity in free float. It seems unlikely that institutions would offer their stake for only an 8% premium considering that the long-term prospects of the company look good.

There is a case for investors to continue holding their stock i.e. not opt for the open offer. This is mainly due to the business upside mentioned above. However, in view of the difference between the offer price and the market price, shareholders of Knoll Pharma can gain from arbitrage.

Exercising the option gives the shareholder an immediate 8% upside. Existing shareholders could buy more stock in the market and submit their existing stock in the tender offer (i.e. arbitrage). The risk however is that their shares may not be accepted in the tender offer, under which circumstance they would be left holding more stock of Knoll Pharma. But if their shares are accepted, investors stand to make an immediate gain. However, an 8% premium to the market price doesn’t seem to be lucrative for Knoll Pharma shareholders.


Equitymaster requests your view! Post a comment on "Knoll Pharma open offer: Pros and cons". Click here!

  

More Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

How Much Money Do You Need to Be a Professional Trader? (Fast Profits Daily)

Sep 17, 2020

In this video I'll answer a question I get asked often: How much capital do I really need to trade the markets for a living? Let's find out...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Sep 25, 2020 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS